There are currently 485 clinical trials in New Orleans, Louisiana looking for participants to engage in research studies. Trials are conducted at various facilities, including Ochsner Clinic Foundation, Ochsner Medical Center Jefferson, Tulane University School of Medicine and Tulane University Health Sciences Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617
Recruiting
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Tulane Cancer Center Office of Clinical Research, New Orleans, Louisiana
Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Register for Updates
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
NCT05322590
Recruiting
The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum. The study will also evaluate if the administration of BXQ-350 with mFOLFOX7 and bevacizumab may diminish oxaliplatin induced sensory neurotoxicity, enabling participants to receive the total and planned doses of mFOLFOX7. All participants will receive BXQ-350 by intravenous (IV) infusion along with stand... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: University Medical Center New Orleans, New Orleans, Louisiana
Conditions: Metastatic Colorectal Carcinoma, Neuropathy
Register for Updates
Prebiotics in Rectal Cancer
NCT05516641
Recruiting
A significant racial disparity in the incidence and mortality of CRC exists in the U.S. with African Americans having CRC incidence and mortality rates that are 20% and 40% higher than the general U.S. population. It has been demonstrated that the gut microbiome impacts tumor development and progression through multiple mechanisms, including impacting the tumoral immune response. However, it is unknown if microbiome modulating treatment can have an impact on CRC outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2023
Locations: Ochsner Medical Center, New Orleans, Louisiana
Conditions: Rectal Cancer
Register for Updates
Single vs. Dual-DCCV in Obese Patients
NCT04539158
Recruiting
Currently, the usual initial strategy for direct current cardioversion (DCCV) typically involves delivering 200J of electricity between two pads placed in the anterior and posterior positions (i.e., one on the chest and one on the back). However, this technique may be less likely to result in successful cardioversion in obese patients (BMI ≥30 kg/m2). Failure to achieve sinus rhythm then necessitates additional shocks, which still may ultimately fail to terminate the patient's atrial fibrillatio... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2023
Locations: Ochsner Medical Center, New Orleans, Louisiana
Conditions: Atrial Fibrillation
Register for Updates
Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors
NCT05159466
Recruiting
The U.S. Department of Health and Human Services (HHS), through the National Institutes of Health (NIH), published Final Human Immunodeficiency Virus (HIV) Organ Policy Equity (HOPE) Act Safeguards and Research Criteria for Transplantation of Organs Infected With HIV. All such transplants must occur under an institutional review board (IRB) approved research protocol that is compliant with federal regulations governing human subjects research. This is an investigator-initiated, observational pro... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/23/2023
Locations: Tulane University Medical Center, New Orleans, Louisiana
Conditions: Human Immunodeficiency Virus, End Stage Renal Disease
Register for Updates
The Effect of Reading Therapy on Newborns
NCT05004857
Recruiting
The primary purpose of this pilot study is to specifically examine the effect of parental reading on the ANS of mother and neonate in the hospital setting. The investigators will examine the effect of live maternal-infant reading on typically developing infants to better understand the physiological benefits of live reading on newborns.
Gender:
All
Ages:
Between 1 minute and 1 week
Trial Updated:
03/21/2023
Locations: Tulane University Health Sciences Center, New Orleans, Louisiana
Conditions: Autonomic Nervous System Diseases
Register for Updates
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT04567420
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, stage II-III, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
All
Ages:
All
Trial Updated:
03/20/2023
Locations: Louisiana State University Health Sciences Center- New Orleans, New Orleans, Louisiana
Conditions: Breast Cancer
Register for Updates
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
NCT05266898
Recruiting
The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection. The secondary objective of the study is to observe short term clinical outcomes of prevalent HPV genotype-specific anogenital infections in adults living with HIV who complete the three-dose Gardasil-9 vaccine series. The clinical hypothesis is that adults with virologically controlled HIV mount a s... Read More
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
03/13/2023
Locations: University Medical Center New Orleans, New Orleans, Louisiana
Conditions: Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology, Cervical Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Oral Cavity Infection
Register for Updates
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT03412643
Recruiting
This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: University Medical Center New Orleans, New Orleans, Louisiana
Conditions: HER2-negative Breast Cancer
Register for Updates
Increasing PrEP With Trans Women in the Deep South
NCT05689281
Recruiting
The goal of this to address barriers and facilitators to PrEP uptake, and encourage adherence among trans women via a single arm stepped wedge clinical trial. The main question is to compare PrEP uptake and adherence outcomes among trans women in the T'Cher intervention to the delayed study arm.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: NO/AIDS Task Force d.b.a. CrescentCare, New Orleans, Louisiana
Conditions: Hiv
Register for Updates
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
NCT03061305
Recruiting
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials. The Strata Trial (STR-001-001) has been initiated by Strata Oncology to evaluate the clinical benefit of systematic comprehensive genomic profiling for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2023
Locations: Ochsner Clinic Foundation, New Orleans, Louisiana
Conditions: Cancer, Adult Solid Tumor, Lymphoma, Multiple Myeloma
Register for Updates
Assessing the Feasibility and Preliminary Impact of a mHealth App on Reducing STI Risk in Black MSM PrEP Users
NCT05395754
Recruiting
The study will recruit 120 Black men who have sex with men (BMSM) from the local area, New Orleans. The main purpose of this research study is to test the effect of a new smartphone application, "PCheck," on reducing the incidence of STIs, compared to routine care through the LSU-Crescent Care Sexual Health/PrEP Clinic.
Gender:
Male
Ages:
Between 18 years and 35 years
Trial Updated:
02/13/2023
Locations: CrescentCare PrEP Clinic, New Orleans, Louisiana +1 locations
Conditions: STI, Sexually Transmitted Diseases, Pre-exposure Prophylaxis
Register for Updates